<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Volonaki, E.</style></author><author><style face="normal" font="default" size="100%">Psarras, S.</style></author><author><style face="normal" font="default" size="100%">Xepapadaki, P.</style></author><author><style face="normal" font="default" size="100%">Psomali, D.</style></author><author><style face="normal" font="default" size="100%">Gourgiotis, D.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Synergistic effects of fluticasone propionate and salmeterol on inhibiting rhinovirus-induced epithelial production of remodelling-associated growth factors</style></title><secondary-title><style face="normal" font="default" size="100%">Clin Exp Allergy</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Albuterol Androstadienes Anti-Inflammatory Agents Bronchi Cell Line Dose-Response Relationship</style></keyword><keyword><style  face="normal" font="default" size="100%">Drug Drug Synergism Enzyme-Linked Immunosorbent Assay Epithelial Cells Fibroblast Growth Factor 2 HeLa Cells Humans Intercellular Signaling Peptides and Proteins Picornaviridae Infections Rhinovirus Vascular Endothelial Growth Factor A</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2006</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pubmed/17014435</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">10</style></number><volume><style face="normal" font="default" size="100%">36</style></volume><pages><style face="normal" font="default" size="100%">1268-73</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Rhinoviruses (RV), the major trigger of acute asthma exacerbations, are able to infect bronchial epithelium and induce production of pro-inflammatory, but also angiogenic and pro-fibrotic mediators. Fluticasone propionate (FP) and salmeterol (S) are clinically effective and act synergistically in controlling persistent asthma; however, their effect on virus-associated asthma is less clear.|The aim of this study was to assess the individual and combined effects of FP and S on RV-induced epithelial production of vascular endothelial growth factor (VEGF) and fibroblast growth factor-2 (FGF-2).|Bronchial epithelial cells (BEAS-2B) were exposed in vitro to RV and were subsequently treated with FP and S, at physiologically relevant concentrations, alone or in combination. VEGF and FGF-2 were measured in the supernatants of these cultures using ELISA.|FP was able to reduce RV-induced VEGF production in a dose-dependent manner. S also induced a smaller reduction; addition of both factors inhibited VEGF synergistically. FGF-2 production was not inhibited by either FP or S alone, but was significantly reduced when both substances were present in the culture.|This study demonstrates that FP and S may synergistically inhibit the production of angiogenic and/or pro-fibrotic factors that are induced after RV infection of BEAS-2B and are implicated in airway remodelling, suggesting that this combination may represent an important therapeutic option on virus-induced asthma.</style></abstract><work-type><style face="normal" font="default" size="100%">Journal Article</style></work-type></record></records></xml>